Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: why No mention of Dresser License under subsequent events
13. Subsequent Events

During the period September 1, 2010 through October 8, 2010, we purchased 215,003 shares of our common stock at an aggregate cost of $24,465 pursuant to our stock buyback program.

On September 20, 2010 we paid $2,642,954 to Wedbush to settle our outstanding loan balance in full.

On September 29, 2010 we received proceeds of $4,557,590 from Deutsche Bank in connection with our ARS settlement. We realized a loss of $648,740 on the settlement.


Share
New Message
Please login to post a reply